Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan R Davis

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Nature Communications|January 6, 2018
KSHV episomes reveal dynamic chromatin loop formation with domain-specific gene regulationMel Campbell, Tadashi Watanabe, Kazushi Nakano, et al.
Journal of Biomedical Materials Research. Part B, Applied Biomaterials|August 25, 2009
Peroxotitanates for biodelivery of metalsJohn C Wataha, David T Hobbs, Petra E Lockwood, et al.
Molecular Therapy. Oncology|October 2, 2025
Design, development, and evaluation of gene therapeutics specific to KSHV-associated diseasesTomoki Inagaki, Jonna Magdallene Espera, Kang-Hsin Wang, et al.
Journal of Mammary Gland Biology and Neoplasia|February 28, 2019
A Syngeneic ErbB2 Mammary Cancer Model for Preclinical Immunotherapy TrialsZsófia Pénzváltó, Jane Qian Chen, Clifford G Tepper, et al.
Journal of Biomedical Materials Research. Part A|August 25, 2009
Titanate particles as agents to deliver gold compounds to fibroblasts and monocytesRyan R Davis, David T Hobbs, Rania Khashaba, et al.
Hormones & Cancer|July 27, 2011
Dual blockade of PKA and NF-κB inhibits H2 relaxin-mediated castrate-resistant growth of prostate cancer sublines and induces apoptosisRuth L Vinall, Christopher M Mahaffey, Ryan R Davis, et al.
Biorxiv : the Preprint Server for Biology|July 28, 2023
KSHV vIL-6 Enhances Inflammatory Responses by Epigenetic ReprogrammingTomoki Inagaki, Kang-Hsin Wang, Ashish Kumar, et al.
Plos Pathogens|November 7, 2023
KSHV vIL-6 enhances inflammatory responses by epigenetic reprogrammingTomoki Inagaki, Kang-Hsin Wang, Ashish Kumar, et al.
Journal of Medicinal Chemistry|February 11, 2021
Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives ThereofRyan R Davis, Baoli Li, Sang Y Yun, et al.
BMC Genomics|April 22, 2010
Genome response to tissue plasminogen activator in experimental ischemic strokeGlen C Jickling, Xinhua Zhan, Bradley P Ander, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Nature Communications|January 6, 2018
KSHV episomes reveal dynamic chromatin loop formation with domain-specific gene regulationMel Campbell, Tadashi Watanabe, Kazushi Nakano, et al.
Journal of Biomedical Materials Research. Part B, Applied Biomaterials|August 25, 2009
Peroxotitanates for biodelivery of metalsJohn C Wataha, David T Hobbs, Petra E Lockwood, et al.
Molecular Therapy. Oncology|October 2, 2025
Design, development, and evaluation of gene therapeutics specific to KSHV-associated diseasesTomoki Inagaki, Jonna Magdallene Espera, Kang-Hsin Wang, et al.
Journal of Mammary Gland Biology and Neoplasia|February 28, 2019
A Syngeneic ErbB2 Mammary Cancer Model for Preclinical Immunotherapy TrialsZsófia Pénzváltó, Jane Qian Chen, Clifford G Tepper, et al.
Journal of Biomedical Materials Research. Part A|August 25, 2009
Titanate particles as agents to deliver gold compounds to fibroblasts and monocytesRyan R Davis, David T Hobbs, Rania Khashaba, et al.
Hormones & Cancer|July 27, 2011
Dual blockade of PKA and NF-κB inhibits H2 relaxin-mediated castrate-resistant growth of prostate cancer sublines and induces apoptosisRuth L Vinall, Christopher M Mahaffey, Ryan R Davis, et al.
Biorxiv : the Preprint Server for Biology|July 28, 2023
KSHV vIL-6 Enhances Inflammatory Responses by Epigenetic ReprogrammingTomoki Inagaki, Kang-Hsin Wang, Ashish Kumar, et al.
Plos Pathogens|November 7, 2023
KSHV vIL-6 enhances inflammatory responses by epigenetic reprogrammingTomoki Inagaki, Kang-Hsin Wang, Ashish Kumar, et al.
Journal of Medicinal Chemistry|February 11, 2021
Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives ThereofRyan R Davis, Baoli Li, Sang Y Yun, et al.
BMC Genomics|April 22, 2010
Genome response to tissue plasminogen activator in experimental ischemic strokeGlen C Jickling, Xinhua Zhan, Bradley P Ander, et al.
Pageof 5